Cannabix Technologies Applauds Canadian Task Force Report on Cannabis Legalization and its Focus on Marijuana Impaired Driving
For immediate release. Vancouver, British Columbia, December 14, 2016: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) After a preliminary review of the findings of the Canadian special task force released on December 13, 2016, on the future regulation of recreational cannabis in Canada, Kal Malhi, President of Cannabix states, “We welcome the recommendations from the Task Force members which speaks to the urgent need to identify and approve a scientific tool to collect court approved evidence of marijuana impaired driving. Cannabix is developing its Cannabix Marijuana Breathalyzer to help law enforcement and employers to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in various jurisdictions. The report confirms that marijuana impaired driving poses an increasing risk to the public and law enforcement needs a tool that can be used at the roadside to collect court admissible evidence of impairment at the time of the test. The report is concrete validation of the work we have been doing at Cannabix in developing our Cannabix Marijuana Breathalyzer and being a leader and early mover in this space.”
The Task Force agrees with experts in law enforcement that impaired driving is a serious issue that exists currently and requires immediate action to protect public safety. The report also confirms that the level of THC in bodily fluids cannot be used to reliably indicate the degree of impairment or crash risk. In addition, the Company notes and applauds the following specific recommendations to provincial Ministers across Canada, which include:
Determining whether to establish a per se limit as part of a comprehensive approach to cannabis-impaired driving and re-examine per se limits should a reliable correlation between THC levels and impairment be established;
Supporting the development of an appropriate roadside drug screening device for detecting THC levels, and invest in these tools;
Investing in baseline data collection and ongoing surveillance and evaluation in collaboration with provinces and territories.
Cannabix Technologies is working to develop a rigorous trial with expedited ethics approval to begin detailed scientific trial testing of the Cannabix Marijuana Breathalyzer. This trial is intended to compare the Cannabix Marijuana Breathalyzer utilizing breath samples with correlated blood samples. The Company plans to use key metrics and guidance from Drugs and Driving Committee (DDC), which is an advisory body to the Canadian Department of Justice on issues relating to drug-impaired driving and has been given a mandate to develop reports regarding drugs that are proposed for zero-tolerance and per se legislation, including cannabis/THC.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact us at info@cannabixtechnologies.com
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financing; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact
For additional information on Cannabix Technologies Inc. please visit our website at http://www.cannabixtechnologies.com or email info@cannabixtechnologies.com
For immediate release. Vancouver, British Columbia, December 14, 2016: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) After a preliminary review of the findings of the Canadian special task force released on December 13, 2016, on the future regulation of recreational cannabis in Canada, Kal Malhi, President of Cannabix states, “We welcome the recommendations from the Task Force members which speaks to the urgent need to identify and approve a scientific tool to collect court approved evidence of marijuana impaired driving. Cannabix is developing its Cannabix Marijuana Breathalyzer to help law enforcement and employers to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in various jurisdictions. The report confirms that marijuana impaired driving poses an increasing risk to the public and law enforcement needs a tool that can be used at the roadside to collect court admissible evidence of impairment at the time of the test. The report is concrete validation of the work we have been doing at Cannabix in developing our Cannabix Marijuana Breathalyzer and being a leader and early mover in this space.”
The Task Force agrees with experts in law enforcement that impaired driving is a serious issue that exists currently and requires immediate action to protect public safety. The report also confirms that the level of THC in bodily fluids cannot be used to reliably indicate the degree of impairment or crash risk. In addition, the Company notes and applauds the following specific recommendations to provincial Ministers across Canada, which include:
Determining whether to establish a per se limit as part of a comprehensive approach to cannabis-impaired driving and re-examine per se limits should a reliable correlation between THC levels and impairment be established;
Supporting the development of an appropriate roadside drug screening device for detecting THC levels, and invest in these tools;
Investing in baseline data collection and ongoing surveillance and evaluation in collaboration with provinces and territories.
Cannabix Technologies is working to develop a rigorous trial with expedited ethics approval to begin detailed scientific trial testing of the Cannabix Marijuana Breathalyzer. This trial is intended to compare the Cannabix Marijuana Breathalyzer utilizing breath samples with correlated blood samples. The Company plans to use key metrics and guidance from Drugs and Driving Committee (DDC), which is an advisory body to the Canadian Department of Justice on issues relating to drug-impaired driving and has been given a mandate to develop reports regarding drugs that are proposed for zero-tolerance and per se legislation, including cannabis/THC.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact us at info@cannabixtechnologies.com
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financing; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact
For additional information on Cannabix Technologies Inc. please visit our website at http://www.cannabixtechnologies.com or email info@cannabixtechnologies.com
